Epoetin alfa biosimilar (Intas BioPharmaceuticals)

阿法依伯汀生物类似药 (Intas BioPharmaceuticals)

Report date: 2022/12/30 16:25:45

Base Information

Drug NameEpoetin alfa biosimilar (Intas BioPharmaceuticals)
Drug Alias Name阿法依伯汀生物仿制药 (Intas Biopharmaceuticals)EPOEpofitRenocelErykine
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIntas Biopharmaceuticals
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A